Summary
Raman HT is a company expert on Raman Spectroscopy (RS) which has developed a revolutionary medical device to diagnose Alzheimer’s Disease (AD) in blood plasma for the first time. Currently, there are only two accurate methods to diagnose AD, expensive, invasive with multiple side effects. Positron Emission Tomography (PET) scans the patient’s brain after being injected with a radioactive marker (cost of €1500) which can cause major allergic reactions. The other method analyzes the cerebrospinal fluid, which requires performing the patient a lumbar puncture. This procedure (relatively expensive, €400) can cause severe headaches, temporary pain of numbness to legs, infections and bleeding into the spinal canal.
There are more than 30 million people living with AD in Europe and more than 7 million people that have not received a diagnostic due to the cost and side effects of the current techniques. Without diagnostic, patients lacks of a proper treatment that improves patients life quality ameliorating the symptoms of the disease. The earlier the diagnosis, the earlier the treatment delaying nursery admission.
Our solution consists of performing RS onto a sample of blood plasma. It is not invasive, has absolutely no side effects and an estimated selling price of €100. Our solution, making AD diagnosis more affordable, can produce net saving of €2,8bn to the European Healthcare system only delaying institutionalization. Our aim is to bring our solution into the market as a reference diagnostic method for screening patients for Alzheimer’s Disease. Alzheimer Disease is a huge problem that Europe needs to address due to the aging population. By 2050, 50% of the total European population will be over 65 years old and more importantly, 1 out 3 will suffer from Alzheimer’s Disease.
There are more than 30 million people living with AD in Europe and more than 7 million people that have not received a diagnostic due to the cost and side effects of the current techniques. Without diagnostic, patients lacks of a proper treatment that improves patients life quality ameliorating the symptoms of the disease. The earlier the diagnosis, the earlier the treatment delaying nursery admission.
Our solution consists of performing RS onto a sample of blood plasma. It is not invasive, has absolutely no side effects and an estimated selling price of €100. Our solution, making AD diagnosis more affordable, can produce net saving of €2,8bn to the European Healthcare system only delaying institutionalization. Our aim is to bring our solution into the market as a reference diagnostic method for screening patients for Alzheimer’s Disease. Alzheimer Disease is a huge problem that Europe needs to address due to the aging population. By 2050, 50% of the total European population will be over 65 years old and more importantly, 1 out 3 will suffer from Alzheimer’s Disease.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/683708 |
| Start date: | 01-07-2015 |
| End date: | 31-10-2015 |
| Total budget - Public funding: | 71 429,00 Euro - 50 000,00 Euro |
Cordis data
Original description
Raman HT is a company expert on Raman Spectroscopy (RS) which has developed a revolutionary medical device to diagnose Alzheimer’s Disease (AD) in blood plasma for the first time. Currently, there are only two accurate methods to diagnose AD, expensive, invasive with multiple side effects. Positron Emission Tomography (PET) scans the patient’s brain after being injected with a radioactive marker (cost of €1500) which can cause major allergic reactions. The other method analyzes the cerebrospinal fluid, which requires performing the patient a lumbar puncture. This procedure (relatively expensive, €400) can cause severe headaches, temporary pain of numbness to legs, infections and bleeding into the spinal canal.There are more than 30 million people living with AD in Europe and more than 7 million people that have not received a diagnostic due to the cost and side effects of the current techniques. Without diagnostic, patients lacks of a proper treatment that improves patients life quality ameliorating the symptoms of the disease. The earlier the diagnosis, the earlier the treatment delaying nursery admission.
Our solution consists of performing RS onto a sample of blood plasma. It is not invasive, has absolutely no side effects and an estimated selling price of €100. Our solution, making AD diagnosis more affordable, can produce net saving of €2,8bn to the European Healthcare system only delaying institutionalization. Our aim is to bring our solution into the market as a reference diagnostic method for screening patients for Alzheimer’s Disease. Alzheimer Disease is a huge problem that Europe needs to address due to the aging population. By 2050, 50% of the total European population will be over 65 years old and more importantly, 1 out 3 will suffer from Alzheimer’s Disease.
Status
CLOSEDCall topic
PHC-12-2015-1Update Date
26-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
